Showing posts with label Parkinson's. Show all posts
Showing posts with label Parkinson's. Show all posts
Thursday, December 5, 2013
Monday, August 5, 2013
The South Florida Bone Marrow Stem Cell Transplant Institute
The South Florida Bone Marrow Stem Cell Transplant Institute
 |
| Dr. Dipnarine Maharaj MD - Medical Director - South Florida Bone Marrow Stem Cell Transplant Institute |
The South Florida Bone Marrow Stem Cell Transplant Institute
(The Institute) is a Joint Commission Accredited Ambulatory Health Care Facility
located at Bethesda Health City, Boynton Beach, Florida.
The program,
which provides totally outpatient bone marrow stem cell transplant services, treated
the first patient in 1998. At that time,
it was under the management of Bethesda Memorial Hospital and functioned as a
unit of the hospital. In 2001 it became
independent of the hospital and is now freestanding and not associated with the
hospital, except that the physicians are on staff at the hospital and may admit
to the inpatient oncology unit at Bethesda Memorial Hospital, or the medical
intensive care unit, if needed by the patient. The Institute received Joint Commission
Accreditation in 2003 and was re-accredited in 2006 and 2009.
Related Content:
Based on the work of Dr. Zheng Cui PhD, Dr. Dipnarine Maharaj MD, FACP, Medical Director of the South Florida Bone Marrow/Stem Cell Transplant Institute
Jul 16, 2013 - Dr. Dipnarine Maharaj is the Medical Director and founder of the South Florida Bone Marrow/Stem Cell Transplant Institute, one of the few ...
Internationally Recognized Stem Cell Transplant Physician & Research in the fight against Cancer, Parkinson's Disease, Leukemia, Alzheimer's Disease, ...
Jul 24, 2013 - Internationally Recognized Stem Cell Transplant Physician & Research in the fight against Cancer, Parkinson's Disease, Leukemia, ...
Dr. Dipnarine Maharaj's Message: The ability of stem cells to repair the cells and tissues of the body is an observation that I have made in the many years that I ...
Dr. Dipnarine Maharaj wrote 2 days ago : The Role of Stem Cells in Regenerative Medicine and ... Stem Cells and Aging Written By Dr. Dipnarine Maharaj M.D..
Related Content:
Local CBS News Story on Dr. Dipnarine Maharaj's Cancer Study ...
www.stemcellrisks.com/local-cbs-news-story-on-dr-dipnarine-maharajs-c...
Dr. Dipnarine Maharaj MD Interview with Turkish Newspaper (2011)
drdipnarinemaharaj.blogspot.com/.../dr-dipnarine-maharaj-md-interview...
Parkinson's & Cancer Expert Dipnarine Maharaj Videos | Dr ...
dipnarinemaharaj.wordpress.com/parkinsons-cancer-expert-dipnarine-m...
Dipnarine Maharaj Introduction to Adult Stem Cells | Dr. Dipnarine ...
dipnarinemaharaj.wordpress.com/.../dipnarine-maharaj-introduction-to-a...
Dipnarine Maharaj | LinkedIn
http:www.linkedin.com/pub/dipnarine-maharaj/2b/435/77
United States - --
View Dipnarine Maharaj's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Dipnarine Maharaj ...South Florida Adult Stem Cell Health Bank - Dr. Dipnarine Maharaj ...
dipnarine maharaj | LinkedIn
Miami/Fort Lauderdale Area - electronics technician at dmelectronics
View dipnarine maharaj's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like dipnarine maharaj ...Dr Dipnarine Maharaj — Blogs, Pictures, and more on WordPress
Wednesday, July 24, 2013
Adult Stem Cell Current Clinical Applications – Hematological Disorders and Malignancies - Dipnarine Maharaj M.D. FACP
Current Clinical Applications
– Hematological Disorders and Malignancies - Dipnarine Maharaj M.D. FACP
 |
| Dr. Dipnarine Maharaj M.D. - Medical Director - South Florida Bone Marrow Stem Cell Transplant Institute |
Adult stem cells have been
successfully used to treat blood disorders, blood cancers, and immune system
disorders, for the last 50 years or so. Such treatments are routine medical procedures
that provide curative protocols.
An adult stem cell transplant, or
hematopoietic stem cell transplant (HSCT), is a procedure in which progenitor
cells that are capable of reconstituting normal bone marrow function are
administered to a patient. HSCT is usually carried out to eliminate a bone marrow
infiltrative process, such as leukemia, or to correct nonmalignant disorders. In
order to carry out a HSCT the patient’s bone marrow is destroyed with high-dose
chemotherapy and radiotherapy and the new stem cells are then transplanted into
the patient.
The
stem cells which are used to replace the bone marrow and restore immune
function are obtained from the patient (an autologous transplant), a donor (an
allogeneic transplant), or from a genetically identical individual e.g.
monozygotic twins (a syngeneic transplant). In order to conduct an autologous
transplant the patient has to be in complete remission and the bone marrow has
to be clean of tumor cells. In the case of allogeneic transplants, the donor
and the recipient are not genetically identical, but they are histocompatible. There
are several different types of allogeneic transplants: HLA (human leukocyte
antigen)-matched sibling, HLA-matched unrelated donor, unmatched donor, and
cord blood transplant. A relatively new
technique is a nonmyeloablative or “mini” allogeneic transplant. In this
procedure the bone marrow is not ablated. Instead, lower doses of chemotherapy
are used to create a space within the bone marrow. The donor stem cells from
the normal donor are then infused into the space, thus creating a chimera –
where both recipient and donor cells coexist within the bone marrow space.
Ultimately, the normal cells will destroy the abnormal stem cells.
Nonmyeloablative transplants are still somewhat experimental; however they are
associated with a lower risk of transplant-related mortality and thus offer a
potential cure to patients who are considered too high-risk for conventional
allogeneic HSCT. Common indications for allogeneic HSCT include:
·
Malignant
disorders:
- Acute
myelogenous leukemia (AML)
- Non-Hodgkin’s
lymphoma (NHL)
- Hodgkin’s
disease
- Acute
lymphoblastic leukemia (ALL)
- Chronic
myeloid leukemia (CML)
- Multiple
myeloma (MM)
- Chronic
lympocytic leukemia (CLL)
·
Nonmalignant
disorders:
- Aplastic
anemia
- Thalassemia
major
- Severe
combined immunodeficiency
- Myelodysplastic
syndromes
- Sickle
cell anemia
What about autologous transplants?
Multiple myeloma remains the most common
indication, followed by lymphoma, and then leukemia. Autoimmune diseases are also considered for
autologous transplant.
Figure 1. Indications for Hematopoietic Stem Cell Transplantation in North America (2005)
Figure 1 illustrates data taken from
the Center for the International Bone Marrow Transplant Registry. The green
shows the number of allogeneic transplants that were carried out for different
disease types and the yellow shows the autologous transplants. From this
illustration it can be seen that the most common type of HTSC for multiple
myeloma is an autologous transplant, whereas for acute lymphoblastic leukemia,
the most common indication is for an allogeneic transplant.
Table
1. 5-Year Disease Free Survival Rate is Dependent Upon Transplant Type
5-Year Disease Free Survival
|
|||
Disease
|
Autologous
Transplantation
|
Allogeneic Transplantation
|
|
AML
|
1st Complete
Remission
|
40%
|
55%
|
AML
|
2nd Complete
Remission
|
30%
|
45%
|
Advanced AML
|
10%
|
20%
|
|
Multiple Myeloma
|
40%
|
35%
|
|
ALL
|
1st Complete
Remission
|
40%
|
|
ALL
|
2nd Complete
Remission
|
25%
|
|
HG Non-Hodgkin’s Lymphoma
|
50%
|
25%
|
|
Hodgkin’s Lymphoma
|
60%
|
||
CML
|
Chronic Phase 1st
Year
|
68%
|
|
CML
|
Chronic Phase >1st
Year
|
53%
|
|
As can be seen in Table 1, different
types of HTSC are better than others for specific diseases. For example, the
5-year survival rate of a patient with multiple myeloma is approximately 40%
with autologous transplant. However, with allogeneic transplants it is
approximately 35. So, for multiple myeloma, an autologous transplant is the
treatment of choice.
Research
has shown that adult stem cells decline in function as we get older, but not in
number. DNA damage and epigenetic modifications present in the older individual
are known to limit the regenerative potential of adult stem cells. Thus, it is
important to consider the age of a patient or stem cell donor, because even though
we may be collecting large number of the cells many of them may be nonfunctional,
and that will obviously have an impact upon the outcome of the transplant
procedure. There is an obvious way around these problems, and that is to
collect and store stem cells when we are young and healthy. The storage of
healthy and functional adult stem cells provides biological insurance for the
treatment of blood malignancies and for future regenerative therapies.
Thursday, July 18, 2013
Subscribe to:
Posts (Atom)